Rufinamide
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
|
|
| Clinical data | |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a609001 |
| Licence data | EMA:Link, US FDA:link |
| Legal status |
|
| Routes of administration |
Oral |
| Identifiers | |
| CAS Number | 106308-44-5  |
| ATC code | N03AF03 (WHO) |
| PubChem | CID: 129228 |
| IUPHAR/BPS | 7470 |
| ChemSpider | 114471  |
| UNII | WFW942PR79 |
| ChEMBL | CHEMBL1201754 |
| Chemical data | |
| Formula | C10H8F2N4O |
| Molecular mass | 238.194 |
|
|
|
|
| (what is this?) (verify) |
|
<templatestyles src="Module:Hatnote/styles.css"></templatestyles>
Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome[1] and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.
Rufinamide was approved by the US Food and Drug Administration on November 14, 2008 as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults. Its official FDA-approved labeling does not mention use in the treatment of partial seizures inasmuch as clinical trials submitted to the FDA were marginal. However, several recent clinical trials suggest that the drug has efficacy for partial seizures [2] It is marketed under the brand name Banzel.[3] It is also marketed in the European Union under the brand name Inovelon.[4]
The mechanism of action of rufinamide is unknown. There is some evidence that rufinamide can modulate the gating of voltage-gated sodium channels,[5] a common target for antiepileptic drugs.[6] A recent study indicates subtle effects on the voltage-dependence of gating and the time course of inactivation in some sodium channel isoforms that could reduce neuronal excitability.[7] However, this action cannot explain the unique spectrum of activity of rufinamide.
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ FDA press release - FDA Approves New Drug to Treat Severe Form of Epilepsy
- ↑ European Public Assessment Report for rufinamide (INOVELON)
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
